Corbus Pharmaceuticals Holdings, Inc. · NASDAQ:CRBP

Corbus Pharmaceuticals — Investor Presentation (June 2022)

19 slides from Corbus Pharmaceuticals's investor presentation, Jun 8, 2022

  1. Slide 1: Partnership Project: CRB-913 oral CB1 inverse agonist for incretin therapy in obesity

    CORBUS \ © PHARMACEUTICALS Partnership Project CRB-913: oral cannabinoid type-1 inverse agonist for superior incretin therapy in obesity June 2022 NASDAQ: CRBP + Corbus!

  2. Slide 2: Forward-looking statements

    This presentation contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of ‘the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's restructuring, tri

  3. Slide 3: Obesity is a global epidemic with a growing treatment market

    Obesity is a global epidemic with a growing treatment market oo @ of worldwide of US adults annual global medical 3" adults projected to projected tobe costs associated with = be obese hy 2029 obese by 2029 obesity (direct & indirect) Global Obesity Rx Spend af $12B i oR a | et 2022 2028 Sources

  4. Slide 4: Injectable incretin analog treatments are establishing a new SoC in obesity

    Injectable incretin analog treatments are establishing a new SoC in obesity GLP-1 receptor agonist BASELINE WEIGHT: 105 kg 2.4% 2.7kg -15.9kg Placebo mWegovy 2.4mg Sources ‘ONCE-WEEKLY tirzepatide injection GLP-1 and GIP dual receptor agonist BASELINE WEIGHT: 104.8 kg 3.1% Placebo mtirzepatide mtirz

  5. Slide 5: Future in obesity is the combination of oral orthogonal mechanisms

    Future in obesity is the combination of oral orthogonal mechanisms Patient Initial Preferences for Weekly Injectable vs. Daily Oral’ View of Evolving Industry Obesity Pipeline Current 2023+ 2026+ 2029+ Next-generation combinations x 2 sansa 2 g ee ri 3 , : = _/ 3 i=) a 668 r-agonist (Pha = & / Cagri

  6. Slide 6: CB1 inverse agonism: an orthogonal MOA for treating obesity

    CB1 inverse agonism: an orthogonal MOA for treating obesity

  7. Slide 7: The endocannabinoid system is an ancient survival mechanism turned enemy in modern times

    The endocannabinoid system is an ancient survival mechanism turned enemy in modern times ¥ THEN: Activating CB1 made us store scarce food as energy (fat deposits) and made us hungry so we would always eat when we found food NOW: Activated CB1 makes us store calorie-rich, abundant food as fat and mak

  8. Slide 8: CB1 activation contributes to "Diabesity"

    CBI activation contributes to “Diabesity” 4 Lipogenesis + Adipogenesis f Inflammation +4 Adiponectin secretion Source(s): Targeting the endocannabinoid system in diabesit: Fact or fiction?, Drua Discovery Today, Deeb et al. Mar 2021

  9. Slide 9: CB1 inverse agonism is clinically validated MOA in obesity

    CB1 inverse agonism is clinically validated MOA in obesity SANOFI uy omen Rimonabant (RIO-Lipids) PHASE 3 STUDY Rimonabant % weight + Tested in multiple large phase 3 studies in obesity loss (RIO) and NAFLD (ADAGIO) + Launched in 37 countries (including EU) (2006) + FDA rejected in 2008 due to risk

  10. Slide 10: 2021 Novo Nordisk pre-clinical study showed combo of semaglutide + Corbus CB1 inverse agonist was additive

    2021 Novo Nordisk pre-clinical study showed combo of semaglutide + Corbus CBI inverse agonist was additive Mouse diet-induced obesity model CORBUS seven CRB-4001 UD-5037) is a 2nd -» Semaglutide (1 nmol/kg) (SC QD) generation CB1 inverse agonist -e CRB-4001 (3mgkg) IP designed to be peripherally res

  11. Slide 11: CRB-913: oral CB1 inverse agonist for combination therapy with incretins

    CRB-913: oral CB1 inverse agonist for combination therapy with incretins (data from preclinical models)

  12. Slide 12: CRB-913 is highly differentiated from first generation CB1 inverse agonists

    CRB-913 is highly differentiated from first generation CB1 inverse agonists 25X lower brain levels compared to rimonabant in DIO mice CRB-913 1281 TT + Binds well to CB1(IC,, <5 nM) and poorly to CB2 (IC; >1,000 nM) mm Rimonabant (10 mg/kg PO QD) CRB-913 (2.5mg/kg PO BID) * Good bioavailability + lo

  13. Slide 13: CRB-913: single agent activity and enhanced combo effect with semaglutide or tirzepatide

    CRB-913: single agent activity and enhanced combo effect with semaglutide or tirzepatide Body weight change (%) at day 18 0.0001 <0.0001 <0.0001 | ° 1 a oS Body Weight Change (%) nv o : o oS All cohorts P < 0.001 compared with vehicle High Fat Diet CRB-913 (2.5 mg/kg PO BID) Semaglutide (10 nmol//kg

  14. Slide 14: CRB-913 reduces food consumption alone or in combination with semaglutide or tirzepatide

    CRB-913 reduces food consumption alone or in combination with semaglutide or tirzepatide x Cumulative Food Intake (g) Food Consumption + CRB-913, semaglutide and > Vehicle “& CRB-913 (2.5mg/kg PO BID) > Semaglutide (10 nmol/kg SC Q3D) + Tirzepatide (5 nmolkg SC 3D) intake reductions CRB-913 (2.5 mg/

  15. Slide 15: CRB-913 reverses leptinemia alone and in combination with semaglutide or tirzepatide

    CRB-913 reverses leptinemia alone and in combination with semaglutide or tirzepatide All cohorts P < 0.001 compared with vehicle um Vetide TI CRB-913 (2.5mg/kg PO BID) war Semaglutide (10 nmolkg SC Q3D) CRB-913 (2.5 mgkkg PO BID) +Semaglutide (10 nmolkg SC Q3D) T Tirzepatide (5 nmol/kg SC Q3D) CRB-9

  16. Slide 16: CRB-913 reduces peak insulin alone or in combination with semaglutide or tirzepatide

    CRB-913 reduces peak insulin alone or in combination with semaglutide or tirzepatide All cohorts P < 0.001 compared with vehicle Insulin (ng/ml) = 5 oO 5 oO 15 ® Vehicle Time at ~CRB-913 (2.5mg/kg PO BID) CRB-913 (2.5 mg/kg PO BID) + © semaglutide (10 nmol/kg SC Q3D) semaglutide (10 nmol/kg SC Q3d)

  17. Slide 17: CRB-913 reduces liver fat alone and in combination with semaglutide or tirzepatide

    CRB-913 reduces liver fat alone and in combination with semaglutide or tirzepatide ¥ semaglutide (10 nmol/kg) CRB-913 (2.5 mg/kg) + 4 semaglutide (10 nmol/kg) CRB-913 (2.5 mg/kg) + tirzepatide (5 nmol/kg) =a A CRB-913 tirzepatide Ci} ce (2.5 mg/kg) (5 nmol/kg) “liver oilred stain Source(s): Company

  18. Slide 18: Next steps and summary of key points

    Next steps and summary of key points Follow-on Steps: ¢ Complete IND-enabling studies (12 months) + Initiate phase 1 study with PK + PD outcomes in overweight individuals (clinical + biomarkers) exploring single agent activity and co-administration with GLP-1 RA

  19. Slide 19: Contact

    Contact: partners@corbuspharma.com if interested in learning more about our CRB-913 program

Corbus Pharmaceuticals Holdings — Investor Presentation (June 2022) on 6ix